Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
+$0.05 today
- Market cap
- $60.08M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.60M
Returns on capital
Acrivon Therapeutics, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-69.2%
avg -8.6%
ROIC
-73.0%
avg -67.4%
ROA
-60.1%
avg -70.0%
Analysis
ROA is currently the strongest return metric at -60.1% versus its period average of -70.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Peter Blume-Jensen | Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer | USD 1.13M | 63 | 2.23M | 7.07% |
Kristina Masson | Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer & Director | USD 851.72K | 46 | 317.25K | 1.01% |
Eric J. Devroe | Chief Operating Officer | USD 784.8K | 47 | — | — |
Mary-Alice Miller | Chief Legal Officer & Corporate Secretary | USD 587.11K | 52 | — | — |
Erick Gamelin | Chief Development Officer | USD 480.72K | 68 | 52.59K | 0.17% |
Adam D. Levy | Chief Financial Officer & Principal Financial Officer | — | 60 | 66.01K | 0.21% |
Jesper V. Olsen | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board | — | — | — | — |
Bruce Close | Vice President of Quality & Compliance | — | — | — | — |
Joon Jung | Vice President & Head of Data Science | — | — | — | — |
Katharine Peterson | Vice President of Finance & Accounting | — | — | 18.03K | 0.06% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 25, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$114,341.39
Sells
11
$41,335.46
Net Transaction Value
+$73,005.93
Net buying
Most Active
Miller Mary
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 22, 26Oct 22, 2026 | Miller Mary Direct | Sell | $943.9$943.92 |
| Oct 5, 26Oct 5, 2026 | Miller Mary Direct | Sell | $585.1$585.06 |
| Aug 25, 26Aug 25, 2026 | Blume-Jensen Peter Direct | Sell | $31K$30,969.03 |
| Aug 18, 26Aug 18, 2026 | Peterson Katharine Direct | Sell | $203$203.01 |
| Aug 18, 26Aug 18, 2026 | Miller Mary Direct | Sell | $371.8$371.85 |
| Aug 18, 26Aug 18, 2026 | Gamelin Erick Direct | Sell | $804$804.00 |
| Aug 18, 26Aug 18, 2026 | Devroe Eric Direct | Sell | $1.2K$1,214.04 |
| Aug 18, 26Aug 18, 2026 | Blume-Jensen Peter Direct | Sell | $2.5K$2,470.29 |
| Aug 18, 26Aug 18, 2026 | Blume-Jensen Peter Indirect | Sell | $972.8$972.84 |
| Aug 4, 26Aug 4, 2026 | Levy Adam D. Direct | Sell | $1.8K$1,792.94 |
1–10 of 14
Summary
Insiders reported 3 buys worth $114,341.39 and 11 sells worth $41,335.46 over the last 12 months. That adds up to net buying of $73,005.93. Miller Mary was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Acrivon Therapeutics, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ACRV's management, answered from reported figures.
Who manages ACRV?
Acrivon Therapeutics, Inc. Common Stock (ACRV) lists 10 active executives. The top listed executive is Adam D. Levy, Chief Financial Officer & Principal Financial Officer.
Are ACRV insiders buying or selling?
Recent insider activity shows net buying of $62.66M.
Continue the stock analysis
Jump to another research area for this company.